DUBLIN–(BUSINESS WIRE)–The “Argininosuccinic Aciduria (ASA) – Market Insights, Epidemiology, and Market Forecast – 2030” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This “Argininosuccinic Aciduria (ASA) – Market Insights, Epidemiology, and Market Forecast -2030” report delivers an in-depth understanding of the historical and forecasted epidemiology and the market trends of argininosuccinic aciduria (ASA) in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The argininosuccinic aciduria (ASA) market report provides current treatment practices, emerging drugs, and their market share of the individual therapies, current and forecasted argininosuccinic aciduria (ASA) market Size from 2017 to 2030, segmented by seven major markets. The report also covers the current treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying market potential.
Argininosuccinic Aciduria (ASA) Diagnosis and Treatment
It covers the details of conventional and current medical therapies and diagnosis available in the argininosuccinic aciduria (ASA) market to treat the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.
The Argininosuccinic Aciduria (ASA) market report gives a thorough understanding of Argininosuccinic aciduria (ASA) by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Argininosuccinic Aciduria (ASA) in the US, Europe, and Japan.
Argininosuccinic Aciduria (ASA) Epidemiology
The persistent argininosuccinic aciduria (ASA) epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical and forecasted argininosuccinic aciduria (ASA) epidemiology segmented as the total incident cases of argininosuccinic aciduria (ASA) and early-onset and late-onset cases of argininosuccinic aciduria. The report includes the Incident scenario of argininosuccinic aciduria (ASA) in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.
Argininosuccinic Aciduria (ASA) Drug Chapters
The drug chapter segment of the argininosuccinic aciduria (ASA) report encloses the detailed analysis of argininosuccinic aciduria (ASA) marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the argininosuccinic aciduria (ASA) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
Treatment of ASA may require the coordinated efforts of a team of specialists ranging from pediatricians, geneticists, dieticians, and physicians who are familiar with metabolic disorders to occupational, speech-language, and physical therapists. A comprehensive approach to treatment is needed to treat children with wide disabilities. Genetic counseling is also recommended for affected individuals and their families. Furthermore, treatment recommendations may be separated into two scenarios: treatment for rapid control of hyperammonemia during metabolic decompensations and interval therapy to prevent the primary manifestations and long-term complications.
Argininosuccinic Aciduria (ASA) Emerging Drugs
ACER-001 is a proprietary, fully taste-masked, immediate-release formulation of sodium phenylbutyrate (NaPB) developed using a microencapsulation process. NaPB helps control blood ammonia levels in conjunction with a restricted diet for people with UCDs. For the treatment of UCDs, NaPB is a prodrug that metabolizes quickly to become phenylacetate that binds to glutamine via acetylation to form phenylacetylglutamine. Phenylacetylglutamine is similar to urea; it contains two moles of nitrogen and is excreted by the kidneys. Through this process, NaPB is an alternate way to excrete excessive nitrogen created by the ineffective processing of ammonia during the urea cycle.
Argininosuccinic Aciduria (ASA) Market Outlook
The argininosuccinic aciduria (ASA) market outlook of the report builds the detailed comprehension of the historical, current, and forecasted argininosuccinic aciduria (ASA) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.
This segment gives a thorough detail of Argininosuccinic Aciduria (ASA) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need for the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
The management and diagnosis of ASA have not advanced significantly in the past decade, but given recent advances in understanding the timing and potential pathogenesis of ASA, it is hopeful that the next decade will bring early diagnostics and novel therapeutics.
Key Topics Covered:
1. Key Insights
2. Argininosuccinic Aciduria (ASA): Market Overview at a Glance
2.1. Market Share (%) Distribution of ASA in 2017
2.2. Market Share (%) Distribution of ASA in 2030
3. Executive summary
5. Disease Overview: Argininosuccinic aciduria
5.2. Signs and Symptoms
5.3. Clinical Characterization
6. Epidemiology and Patient Population
6.1. Key Findings
6.2. Total Incident Population of Argininosuccinic Aciduria in 7MM
6.3. Assumptions and Rationale: 7MM
7. Treatment and Management
8. Unmet Needs
9. Key Cross Competition
10. Marketed Drugs
10.1. Buphenyl: Horizon Therapeutics
10.1.1. Product Description
10.1.2. Regulatory milestones
10.1.3. Other Developmental Activities
10.1.4. Safety and Efficacy
10.1.5. Product Profile
10.2. Ravicti: Horizon Therapeutics
11. Emerging Therapies
11.1. ACER-001: Acer Therapeutics
11.1.1. Product Description
11.1.2. Other developmental activities
11.1.3. Clinical Development
11.1.4. Safety and Efficacy
11.1.5. Product Profile
11.2. In vivo exosome-based therapy: Evox Therapeutics
12. Argininosuccinic aciduria: Seven Major Market Analysis
12.1. Key Findings
12.2. Market Size of Argininosuccinic aciduria in the 7MM
13. Market Outlook
13.1. United States Market Size
13.1.1. Total market size of Argininosuccinic aciduria in the United States
13.1.2. Market size of Argininosuccinic aciduria by Therapies in the US
13.2. Germany Market Size
13.3. France Market Size
13.4. Italy Market Size
13.5. Spain Market Size
13.6. UK Market Size
13.7. Japan Market Size
14. Market Drivers
15. Market Barriers
16. Market Access
17. SWOT Analysis
18. Case studies
18.1. First Reported Case of Parkinsonism in a Patient with Argininosuccinate Lyase Deficiency
18.2. Argininosuccinic Acid Lyase Deficiency Missed by Newborn Screen
18.3. Late-onset argininosuccinic aciduria associated with hyperammonemia triggered by influenza infection in an adolescent: A case report
19. KOL Views
- Horizon Therapeutics
- Acer Therapeutics
- Evox Therapeutics
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/fuzkpb
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900